Good Start Genetics, Inc. , a Boston, MA-based provider of clinically relevant genetic information to physicians , finalized an $18m Series A financing.
The round was led by OrbiMed Advisors, Safeguard Scientifics, Inc. (NYSE: SFE) and SV Life Sciences.
The new capital will be used to complete the development and launch of the company’s pre-pregnancy genetic test, which utilizes advanced DNA sequencing technology to screen for a panel of genetic disorders including those recommended by the American Congress of Obstetricians and Gynecologists (ACOG) and the American College of Medical Genetics (ACMG).
The company expects to launch the test exclusively through board certified physicians in the U.S. starting in 2011.
In conjunction with the funding, Don Hardison, former COO of LabCorp and CEO of Exact Sciences, has been appointed President, CEO and Director of Good Start Genetics.
The company’s board of directors is chaired by Marc Beer, former CEO of ViaCell, and also includes:
– Robert Carpenter, Director of the Genzyme Corporation;
– Carl Gordon, General Partner at OrbiMed Advisors;
– Gary Kurtzman, Managing Director at Safeguard Scientifics;
– Lutz Giebel, Managing Partner at SV Life Sciences.
Good Start Genetics received initial seed financing from the Massachusetts Life Sciences Center’s Accelerator Program.